FDA Chief Scientist Ostroff Named Acting Head With Hamburg On Way Out
This article was originally published in The Rose Sheet
Margaret Hamburg’s background in public health, as opposed to academic medicine, was off-putting to some in pharma initially, but she’ll leave the agency in March with high drug approval numbers and praise from industry groups. Chief Scientist Stephen Ostroff has been named acting head, and some speculate that Robert Califf, newly appointed deputy commissioner for medical products and tobacco, is in line to succeed Hamburg on a permanent basis.
You may also be interested in...
Newly confirmed FDA Commissioner Robert Califf should not assume he will be leaving once a new president arrives, a Republican-appointed predecessor says.
Outgoing commissioner gives a forceful defense of the agency’s regulatory authority and warns that lowering drug approval standards would be detrimental to both patients and industry.
Susan Mayne brings “new strength and focus to CFSAN” and medical countermeasures expert Luciana Borio moves to chief scientist role. Hamburg offers previews on leadership approaches of Stephen Ostroff and Robert Califf.